354 related articles for article (PubMed ID: 31668632)
21. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
22. [Phosphate metabolism and iron deficiency].
Yokoyama K
Clin Calcium; 2016 Feb; 26(2):241-9. PubMed ID: 26813504
[TBL] [Abstract][Full Text] [Related]
23. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
24. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
26. Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.
Vaziri ND; Nunes ACF; Said H; Khazaeli M; Liu H; Zhao Y; Jing W; Cogburn K; Alikhani L; Lau WL
Nephrol Dial Transplant; 2020 Jul; 35(7):1136-1144. PubMed ID: 32514572
[TBL] [Abstract][Full Text] [Related]
27. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
Iida A; Matsushita M; Ohta T; Yamada T
J Vet Med Sci; 2020 Mar; 82(3):379-386. PubMed ID: 31996496
[TBL] [Abstract][Full Text] [Related]
28. The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease.
Lau WL; Vaziri ND; Nunes ACF; Comeau AM; Langille MGI; England W; Khazaeli M; Suematsu Y; Phan J; Whiteson K
J Pharmacol Exp Ther; 2018 Dec; 367(3):452-460. PubMed ID: 30287477
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
[TBL] [Abstract][Full Text] [Related]
30. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
[TBL] [Abstract][Full Text] [Related]
31. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
[TBL] [Abstract][Full Text] [Related]
32. Ferric citrate: cardio- and renoprotective in chronic kidney disease?
Hanudel MR
Kidney Int; 2019 Dec; 96(6):1277-1279. PubMed ID: 31759486
[TBL] [Abstract][Full Text] [Related]
33. Genetic background influences cardiac phenotype in murine chronic kidney disease.
Neuburg S; Dussold C; Gerber C; Wang X; Francis C; Qi L; David V; Wolf M; Martin A
Nephrol Dial Transplant; 2018 Jul; 33(7):1129-1137. PubMed ID: 29309658
[TBL] [Abstract][Full Text] [Related]
34. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
35. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease.
Durlacher-Betzer K; Hassan A; Levi R; Axelrod J; Silver J; Naveh-Many T
Kidney Int; 2018 Aug; 94(2):315-325. PubMed ID: 29861060
[TBL] [Abstract][Full Text] [Related]
37. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
38. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
39. Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.
Maruyama N; Otsuki T; Yoshida Y; Nagura C; Kitai M; Shibahara N; Tomita H; Maruyama T; Abe M
Am J Nephrol; 2018; 47(6):406-414. PubMed ID: 29874654
[TBL] [Abstract][Full Text] [Related]
40. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
